Roles of induced expression of MAPK phosphatase-2 in tumor development in RET-MEN2A transgenic mice

Oncogene

Volumn 27, Issue 43, 2008, Pages 5684-5695

  Hasegawa, T ^a   Enomoto, A ^a,b   Kato, T ^a   Kawai, K ^a   Miyamoto, R ^a   Jijiwa, M ^a   Ichihara, M ^c   Ishida, M ^a   Asai, N ^a   Murakumo, Y ^a   Ohara, K ^a   Niwa, Y ^a   Goto, H ^a   Takahashi, M ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c CHUBU UNIVERSITY   (Japan)

Author keywords

Cell cycle; Cell proliferation; MEN2A; MKP 2; RET

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 2; MUTANT PROTEIN; PHOSPHATASE; PROTEIN RET; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALIVARY GLAND CARCINOMA; SIPPLE SYNDROME; THYROID MEDULLARY CARCINOMA; TRANSGENIC MOUSE;

ANIMALS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; G2 PHASE; MICE; MICE, TRANSGENIC; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2A; NEOPLASMS, EXPERIMENTAL; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; PROTO-ONCOGENE PROTEINS C-RET;

MUS MUSCULUS;

EID: 52949106459     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2008.182     Document Type: Article

References (52)

1. Airaksinen MS, Saarma M. (2002). The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci 3: 383-394.
2. Asai N, Iwashita T, Matsuyama M, Takahashi M. (1995). Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations. Mol Cell Biol 15: 1613-1619.
3. Asai N, Jijiwa M, Enomoto A, Kawai K, Maeda K, Ichiahara M et al. (2006). RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int 56: 164-172.
4. Cadalbert L, Sloss CM, Cameron P, Plevin R. (2005). Conditional expression of MAP kinase phosphatase-2 protects against genotoxic stress-induced apoptosis by binding and selective dephosphorylation of nuclear activated c-jun N-terminal kinase. Cell Signal 17: 1254-1264.
5. Carlson KM, Dou S, Chi D, Scavarda N, Toshima K, Jackson CE et al. (1994). Single missense mutations in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 91: 1579-1583.
6. Dickinson RJ, Keyse SM. (2006). Diverse physiological functions for dual-specificity MAP kinase phosphatases. J Cell Sci 119: 4607-4615.
7. Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al. (1993). Mutations in the RET protooncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2: 851-856.
8. Edery P, Lyonnet S, Mulligan LM, Pelet A, Dow E, Abel L et al. (1994). Mutations of the RET protooncogene in Hirschsprung's disease. Nature 367: 378-380.
9. Eng C. (1999). RET proto-oncogene in the development of human cancer. J Clin Oncol 17: 380-393.
10. Enomoto A, Murakami H, Asai N, Morone N, Watanabe T, Kawai K et al. (2005). Akt/PKB regulates actin organization and cell motility via Girdin/APE. Dev Cell 9: 389-402.
11. Farooq A, Zhou MM. (2004). Structure and regulation of MAPK phosphatases. Cell Signal 16: 769-779.
12. Fukuda T, Asai N, Enomoto A, Takahashi M. (2005). Activation of c-Jun amino-terminal kinase by GDNF induces G2/M cell cycle delay linked with actin reorganization. Genes Cells 10: 655-663.
13. Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PL, Mulligan LM et al. (1997). Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. J Clin Endocrinol Metab 82: 3902-3904.
14. Guan KL, Butch E. (1995). Isolation and characterization of a novel dual specific phosphatase, HVH2, which selectively dephosphorylates the mitogen-activated protein kinase. J Biol Chem 270: 7197-7203.
15. Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, Liu D et al. (2002). Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62: 6414-6417.
16. Hofstra RM, Landvaster RM, Ceccherini I, Stulp RP, Stelwagen T, Luo Y et al. (1994). A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 367: 375-376.
17. Kao GD, McKenna WG, Maity A, Blank K, Muschel RJ. (1997). Cyclin B1 availability is a rate-limiting component of the radiation-induced G2 delay in HeLa cells. Cancer Res 57: 753-758.
18. Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M et al. (2000). Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2a mutation. Cancer Res 60: 5254-5260.
19. Kawai K, Jijiwa M, Shimono Y, Kurokawa K, Murakumo Y, Ichihara M et al. (2003). Establishment and characterization of mouse mammary carcinoma cell lines expressing RET with a multiple endocrine neoplasia 2A mutation. Cancer Sci 94: 992-997.
20. Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M et al. (2005). The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 96: 143-148.
21. Lundberg AS, Hahn WC, Gupta P, Weinberg RA. (2000). Genes involved in senescence and immortalization. Curr Opin Cell Biol 12: 705-709.
22. Misra-Press A, Rim CS, Yao H, Roberson MS, Stork PJ. (1995). A novel mitogen-activated protein kinase phosphatase. Structure, expression, and regulation. J Biol Chem 270: 14587-14596.
23. Moore MW, Klein RD, Fariñas I, Sauer H, Armanini M, Phillips H et al. (1996). Renal and neuronal abnormalities in mice lacking GDNF. Nature 382: 76-79.
24. Mulligan LM, Kwok JB, Healey CS, Elsdon MJ, Eng C, Gardner E et al. (1993). Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460.
25. Murphy LO, Blenis J. (2006). MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31: 268-275.
26. Norbury C, Nurse P. (1992). Animal cell cycles and their control. Annu Rev Biochem 61: 441-470.
27. Owens DM, Keyse SM. (2007). Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene 26: 3203-3213.
28. Park M, Chae HD, Yun J, Jung M, Kim YS, Kim SH et al. (2000). Constitutive activation of cyclin B1-associated cdc2 kinase overrides p53-mediated G2-M arrest. Cancer Res 60: 542-545.
29. Pichel JG, Shen L, Sheng HZ, Granholm AC, Drago J, Grinberg A et al. (1996). Defects in enteric innervation and kidney development in mice lacking GDNF. Nature 382: 73-76.
30. Pines J. (1999). Four-dimensional control of the cell cycle. Nat Cell Biol 1: E73-E79.
31. Porter LA, Donoghue DJ. (2003). Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 5: 335-347.
32. Romeo G, Ronchetto P, Luo Y, Barone V, Seri M, Ceccherini I et al. (1994). Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 367: 377-378.
33. Rosenthal A. (1999). The GDNF protein family: gene ablation studies reveal what they really do and how. Neuron 22: 201-203.
34. Sánchez MP, Silos-Santiago I, Frisén J, He B, Lira SA, Barbacid M. (1996). Renal agenesis and the absence of enteric neurons in mice lacking GDNF. Nature 382: 70-73.
35. Santana C, Ortega E, García-Carrancá A. (2002). Oncogenic H-ras induces cyclin B1 expression in a p53-independent manner. Mutat Res 508: 49-58.
36. Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M et al. (1995). Activation of RET as a dominant transforming gene by germ line mutations of MEN2A and MEN2B. Science 267: 381-383.
37. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. (1994). Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367: 380-383.
38. Sewing A, Wiseman B, Lloyd AC, Land H. (1997). High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol 17: 5588-5597.
39. Shen WH, Wang J, Wu J, Zhurkin VB, Yin Y. (2006). Mitogen-activated protein kinase phosphatase 2: a novel transcription target of p53 in apoptosis. Cancer Res 66: 6033-6039.
40. Shirane D, Sugao K, Namiki S, Tanabe M, Iino M, Hirose K. (2004). Enzymatic production of RNAi libraries from cDNAs. Nat Genet 36: 190-196.
41. Smith DP, Houghton C, Ponder BA. (1997). Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15: 1213-1217.
42. Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK et al. (2000). Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60: 4000-4004.
43. Takahashi M. (2001). The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 12: 361-373.
44. Takizawa CG, Morgan DO. (2000). Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol 12: 658-665.
45. Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schönthal AH, Katula KS et al. (1999). Mechanisms of G2 arrest in response to overexpression of p53. Mol Biol Cell 10: 3607-3622.
46. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD et al. (1996). Characterization of a multicomponent receptor for GDNF. Nature 382: 80-83.
47. Uchida M, Enomoto A, Fukuda T, Kurokawa K, Maeda K, Kodama Y et al. (2006). Dok-4 regulates GDNF-dependent neurite outgrowth through downstream activation of Rap1 and mitogen-activated protein kinase. J Cell Sci 119: 3067-3077.
48. Wang J, Shen WH, Jin YJ, Brandt-Rauf PW, Yin Y. (2007). A molecular link between E2F-1 and the MAPK cascade. J Biol Chem 282: 18521-18531.
49. Watanabe T, Ichihara M, Hashimoto M, Shimono K, Shimoyama Y, Nagasaka T et al. (2002). Characterization of gene expression induced by RET with MEN2A or MEN2B mutation. Am J Pathol 161: 249-256.
50. Woods D, Parry D, Cherwinski H, Bosch E, Lees E, McMahon M. (1997). Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol 17: 5598-5611.
51. Yuan J, Krämer A, Matthess Y, Yan R, Spänkuch B, Gätje R et al. (2006). Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene 25: 1753-1762.
52. Yuan J, Yan R, Krämer A, Eckerdt F, Roller M, Kaufmann M et al. (2004). Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 23: 5843-5852.